Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panobinostat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Panobinostat. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-005252-41 Sponsor Protocol Number: CLBH589B2402B Start Date*: 2013-08-23
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: An open-label multi-center single agent panobinostat rollover protocol for patients who have completed a previous Novartis-sponsored panobinostat study and are judged by the investigator to benefit...
    Medical condition: Hematologic malignancies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018699-26 Sponsor Protocol Number: CLBH589BDE05T Start Date*: 2010-10-25
    Sponsor Name:Goethe Universität Frankfurt
    Full Title: Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST)
    Medical condition: MDS and AML in patients with high risk features after hemapoietic stem cell transplantation with reduced conditioning
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003175-45 Sponsor Protocol Number: TRIO 016 Start Date*: 2009-01-12
    Sponsor Name:Cancer International Research Group
    Full Title: A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer
    Medical condition: HER-2 positive locally recurrent or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003527-22 Sponsor Protocol Number: CINC424A2X01B Start Date*: 2015-04-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to...
    Medical condition: This roll-over study is designed to accept patients with varied disease origins. Please refer to the parent protocol for the disease background information and rationale for use of ruxolitinib in t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DE (Trial now transitioned) GR (Completed) HU (Completed) SE (Trial now transitioned) PT (Completed) BG (Completed) FR (Completed) SK (Completed) DK (Completed) SI (Completed) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001564-19 Sponsor Protocol Number: CLBH589D2222 Start Date*: 2016-04-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexameth...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) NO (Completed) DE (Completed) NL (Completed) HU (Completed) GR (Completed) PL (Completed) CZ (Completed) PT (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000175-13 Sponsor Protocol Number: FIL_PanAL10 Start Date*: 2011-04-26
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult...
    Medical condition: Patient has a history of DLBCL according to the WHO classification. with progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for in...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000764-15 Sponsor Protocol Number: ETAL-4 Start Date*: 2017-12-11
    Sponsor Name:Goethe Universität Frankfurt / Universitätsklinikum Frankfurt
    Full Title: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs....
    Medical condition: High risk acute myeloid leukemia or myelodysplastic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003239-21 Sponsor Protocol Number: CLBH589D2001X Start Date*: 2014-12-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003016-35 Sponsor Protocol Number: CLBH589E2214 Start Date*: 2008-10-07
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio Fase II de Panobinostat oral, en pacientes adultos con Linfoma de Hodgkin clásico refractario/en recaida, después de fallo a dosis altas de quimioterapia con transfusión autóloga de células...
    Medical condition: Linfoma de Hodgkin clásico refractario/en recaída
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010548-32 Sponsor Protocol Number: CLBH589H2101 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic...
    Medical condition: Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Completed) GB (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002449-19 Sponsor Protocol Number: LBH589C2204 Start Date*: 2008-05-08
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with...
    Medical condition: metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015507-52 Sponsor Protocol Number: CLBH589D2308 Start Date*: 2009-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
    Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002986-30 Sponsor Protocol Number: CLBH589B2116 Start Date*: 2010-01-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia
    Medical condition: refractory or relapsed acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000842-36 Sponsor Protocol Number: HM12/10174 Start Date*: 2012-07-26
    Sponsor Name:University of Leeds
    Full Title: A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients
    Medical condition: Multiple myeloma in the relapsed and relapsed/refractory stage
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014846-26 Sponsor Protocol Number: CLBH589E2301 Start Date*: 2010-05-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high do...
    Medical condition: Patients with classical Hodgkine's Lymphoma (HL), who achieved a complete response following high dose chemotherapy (HDT) and autologous stem cell transplant (AHSCT).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (Completed) NL (Completed) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005847-29 Sponsor Protocol Number: MM-VPD-2011 Start Date*: 2012-02-15
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy
    Medical condition: Multiple Myeloma patients candidate to high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000240-94 Sponsor Protocol Number: CLEAR0001 Start Date*: 2012-05-09
    Sponsor Name:Aarhus University Hospital
    Full Title: The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study
    Medical condition: Human Immunodeficiency Virus (HIV) Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020172 HIV infection NOS LLT
    14.1 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002983-32 Sponsor Protocol Number: CLBH589B2213 Start Date*: 2009-06-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
    Medical condition: Patients with refractory de novo or secondary acute myelogenous leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003176-21 Sponsor Protocol Number: TRIO 017 Start Date*: 2008-12-31
    Sponsor Name:Cancer International Research Group
    Full Title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer
    Medical condition: Women with HER-2 negative locally recurrent or metastatic breast cancer;
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005110-58 Sponsor Protocol Number: 64024 Start Date*: 2018-06-14
    Sponsor Name:Medical Centre Leeuwarden
    Full Title: Efficacy of a predefined vitamin D dosing regimen in vitamin D-insufficient multiple myeloma patients.
    Medical condition: Hypovitaminosis D
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 22:24:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA